Fox Christine Ann 4

What Happened
Christine Ann Fox, Chief Financial Officer of Mereo BioPharma Group plc (MREO), received three equity awards (classified as derivative securities) on February 1, 2026 totaling 701,000 shares: 315,750; 105,250; and 280,000. Each grant is reported at $0.00 per share (no purchase price shown). These are awards/grants (code A), not open‑market purchases or sales — they represent compensation subject to vesting rather than an immediate investment or divestment.

Key Details

• Transaction date: February 1, 2026 (reported on Form 4 filed Feb 2, 2026 — timely filing).
• Grants: 315,750; 105,250; and 280,000 derivative shares; all reported at $0.00 per share. Total = 701,000 shares.
• Shares owned after transaction: Not specified in the summary provided. (Check full Form 4 for total beneficial ownership.)
• Footnotes in filing:
  • F1: 25% of one grant vests Feb 1, 2027, remainder vests in equal monthly installments over the next three years.
  • F3: One grant vests in substantially equal monthly installments over one year from Feb 1, 2026.
  • F2: Each American Depositary Share (ADS) equals five ordinary shares (filing notes ADS/ordinary share relationship).
• No 10b5‑1 plan or tax‑withholding/cashless exercise details are indicated in the provided summary.

Context
These are compensation awards (derivative securities) that vest over time — they do not represent an immediate purchase of shares that would signal a current market bet. Awards with $0.00 reported price typically mean the insider will receive or be able to acquire ordinary shares/ADS subject to the listed vesting schedules. For retail investors, such grants are common for executives and are primarily an employment/retention matter rather than a direct buy or sell signal.